Craniopharyngioma difficulty in management
EANS Academy. ma'aya A. 09/25/19; 275324; EP04075
Dr. Alhareth ma'aya
Dr. Alhareth ma'aya

Access to this content is reserved for EANS members and attendees of this event. Click here to become an EANS member and gain your access to the full content of the EANS Academy


Abstract
Discussion Forum (0)
Rate & Comment (0)
Craniopharyngiomas are relatively benign (WHO grade I) neoplasms that typically arise in the sellar/suprasellar region. They account for ~1-5% of primary brain tumours, and can occur anywhere along the infundibulum (from the floor of the third ventricle, to the pituitary gland).
Craniopharyngioma management is challenging. Although histology is benign, the tumour can be clinically aggressive with local invasion and frequent recurrences. Extensive morbidity may be present at diagnosis and furthermore, occurs as a consequence of neurosurgery and radiotherapy. Hypothalamic symptoms can have a devastating effect on quality of life and may reduce life expectancy. This case highlights both the challenge of managing hyperphagia and morbid obesity and the importance of initial treatment preserving existing hypothalamic function and the need to avoid tumour recurrence and further surgery.
We will present our experience in KHCC over the last 12 years that highlights the significant morbidity associated with the diagnosis of craniopharyngioma, the sequelae of treatment with neurosurgery and radiotherapy, and the challenges for the endocrinologist in deciding an optimal care.
Craniopharyngiomas are relatively benign (WHO grade I) neoplasms that typically arise in the sellar/suprasellar region. They account for ~1-5% of primary brain tumours, and can occur anywhere along the infundibulum (from the floor of the third ventricle, to the pituitary gland).
Craniopharyngioma management is challenging. Although histology is benign, the tumour can be clinically aggressive with local invasion and frequent recurrences. Extensive morbidity may be present at diagnosis and furthermore, occurs as a consequence of neurosurgery and radiotherapy. Hypothalamic symptoms can have a devastating effect on quality of life and may reduce life expectancy. This case highlights both the challenge of managing hyperphagia and morbid obesity and the importance of initial treatment preserving existing hypothalamic function and the need to avoid tumour recurrence and further surgery.
We will present our experience in KHCC over the last 12 years that highlights the significant morbidity associated with the diagnosis of craniopharyngioma, the sequelae of treatment with neurosurgery and radiotherapy, and the challenges for the endocrinologist in deciding an optimal care.
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies